New Innovations in Cancer Research

Posted on by

Here are a few highlights of cancer research news that have recently caught my attention:

  • In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers at Johns Hopkins found that on average patients treated with nivolumab lived 3.2 months longer than those receiving chemotherapy. Results of the trial have been published in NEJM.
  • The European Society for Medical Oncology (ESMO) recently announced the publication of the ESMO Magnitude of Clinical Benefits Scale, a tool to assist oncologists in assessing effective cancer medicines for their patients. Read more about this tool in Annals of Oncology. Continue reading →

Preview the New Library Catalog and Let Us Know What You Think!

Posted on by

On June 15, 2015, the Library will be launching Tri-Cat 2.0 — a new version of the online catalog we share with The Rockefeller University and Weill Cornell Medical Libraries.  The new enhancements provide a streamline layout which will allow users to access content from their home institution as well as understand other collections available to them. Take a moment to preview and explore the new catalog.

There is still time to let us know what you think. We encourage you to submit your feedback while on the site or via this link to the Catalog Feedback Form.  Your insights will help us to further refine the look and feel of Tri-Cat!

A Nutrition Science Coverage Hoax, ASCO Highlight Videos, and more Blog Buzz

Posted on by

Some recent news from around the internet…

  • For those unable to make it out to Chicago, the ASCO meeting videos are available online. Check out the free series of brief Highlights of the Day organized by specialty.
  • Kevin Smith of Duke discusses attempts by publishers to control where authors may post and link to their own work during embargo periods. He then goes on to explain why this concept translates poorly into the real academic publishing world. According to Smith;

It appears that Elsevier is making a distinction between an author’s personal website or blog and the repository at the institution where that author works. Authors are, I think, able to post final manuscripts to the former for public access, but posting to the latter must be restricted only to internal users for the duration of the newly-imposed embargo periods. – See more

Continue reading →